Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Menlo Therapeutics; VYNE Therapeutics
- 25 Feb 2020 According to an Menlo Therapeutics media release, the company will host a conference call and webcast on Wednesday, February 26, 2020 to discuss the results from this study.
- 07 Feb 2020 Status changed from active, no longer recruiting to completed.
- 31 Oct 2019 According to a Menlo Therapeutics media release, the company expects to report top-line data from this trial in January or February of 2020.